MAP Pharmaceuticals to present new analyses on LEVADEX from FREEDOM-301 Phase 3 clinical trial
MAP Pharmaceuticals to present new analyses on LEVADEX from FREEDOM-301 Phase 3 clinical trial
MAP Pharmaceuticals, Inc. announced today it will present new analyses from the FREEDOM-301 Phase 3 clinical trial in a late breaker session at the 52nd Annual Scientific Meeting of the American Headache Society (AHS) in Los Angeles, California on Friday, June 25 from 3:30 to 4:00 pm PT. The presentation will show that the Company’s investigational LEVADEX™ orally inhaled migraine therapy was …
Read more on News-Medical-Net
Related posts:
- MAP Pharmaceuticals Presents Analyses Showing LEVADEX Effective when Administered at Various Times in Migraine Cycle …
- How herbs and Natural Remedy work for Headache?
- Struggling With Chronic Sinus & Headaches? Cayenne Pepper Nasal Spray May Be Your Savior
- New York Times Hot Pepper Headache Remedy Is Nothing New
- Vendor Risk Management The New Headache For Data Outsourcers?